Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Overview of attention for article published in New England Journal of Medicine, September 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 2 Bluesky posts from 2 Bluesky users, with an upper bound of 159 followers.

RP @jimcatto.bsky.social: Although self-citing .. the Niagara RCT will change neoadjuvant Rx (albeit maybe briefly) .... www.nejm.org/doi/full/10.... ....

Although self-citing .. the Niagara RCT will change neoadjuvant Rx (albeit maybe briefly) .... www.nejm.org/doi/full/10.... ....

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.